About Us

Developing cutting- edge cell therapies

Biosyngen was established in Singapore on 1 July 2016 as an immuno-oncology company. It adheres to a global strategy to serve patients worldwide with scalable GMP production capability and broad clinical network.

Giving Cancer
Patients a
Second Chance
  • Developing cutting-edge immunotherapies to address unmet needs in oncology.
  • Advancing R&D through our network of international partners.
  • Achieving better outcomes for cancer patients.

Core Management with diverse expertise & experience.
Multinational Scientific & Clinical talents and KOLs

Prof. Wolfgang

Scientist & Pipeline Inventor, Biosyngen

Director of Department of Research Unit Gene Vectors,
 Helmholtz Center Munich

Associate professor of Ludwig-Maximilians-Universität (LMU) München

Löffler-Frosch Award of the German Society of Virology,
 Aronson Award of the City of Berlin

Published multiple articles on Epstein-Barr (EB) virus

Prof. Jules Hoffmann

Scientific Advisor, Biosyngen

Nobel prize in Physiology (2011)

Discover Toll like receptor, major milestone in immunology

President in French academy of Sciences (2007-2008)

Prof. Scott

Scientist & Pipeline Inventor, Biosyngen

Group Leader of the Cellular Immunology Laboratory at QIMR
 Berghofer Medical Research Institute

Involved in the initial mapping of the 1st Epstein-Barr virus T cell epitopes,
a critical step for the advancement of the field

Study focus: CD8-positive T cells for EBV infection antigen
presentation & T cell recognition

Prof. Renata

Scientist & Pipeline Inventor, Biosyngen

Research focus: CAR-T and other immunotherapies

Director, Institute of Translational Immune-Oncology,
University Hospital Cologne & Professor, Hannover Medical School

Special Fellow, Leukemia and Lymphoma Society & Research Fellow,
National Cancer Institute,NIH K01/Howard Temin/US Stop Cancer/USC
and UCLA career development award

Prof. Lam Kong Peng

Scientist & Pipeline Inventor, Biosyngen

Executive director of A*STAR SIgN

Professor in Yong Loo Lin School of Medicine, NUS

Vice-President of the Asian Federation of Biotechnology (AFOB)

Jean-Paul Thiery

Chief Scientist, Biosyngen

Pioneer in elucidating the mechanism of Epithelial-Mesenchymal

Transition  (cancer metastases)

"World"s Top2% Scientists Ranking” No.2 in Clinical Medicine field

Member of French Academy of Science

Principle investigator, Guangzhou Laboratory

Emeritus Director of Research, Gustave Roussy Cancer Center, France

Former Head, CNRS Unit at Ecole Normale Superieure, Paris, France

Former Head, Department of Biochemistry, Yong Loo Lin School of Medicine,
National University of Singapore

Awardee of Knight of the French National Order of Merit (1997)
Laureate of French Academy of Medicine (2000) &
Knight in the French Legion of Honor (2009)

Five patents, Publish 500 peer-reviewed papers , H Index 129.

Core Management
  • Co- Founder & CEO
    Dr. Michelle Chen
  • Co- Founder & CMO
    Dr. Han Deping
  • Co- Founder & CSO
    Dr. Cecilia Zhang
  • CFO
    Vincent Zheng
  • VP Regulatory Affairs and CMC
    Dr. Jing Han
  • CBO
    Isaac Chow

With the recent advances of cutting-edge biotechnologies, immunotherapy is now in a good position to declare war against all cancers.


Starting in 2010, CD19 CAR-T cells endowed to recognize a marker on a malignant blood disease called leukemia induced complete remission and become now available for a subset of leukemic patients worldwide.


The beginning of this century has seen an exceptional improvement in therapies for a limited number of cancers, such as melanoma, using checkpoint inhibitors. Patients received several doses of antibodies to temporarily boost the immune system. However, this strategy needs to be improved or complemented by T-cell-based therapies.


In the late 20th century, bone marrow transplantation, which reconstituted patients’ immune system after chemotherapy or radiotherapy, and tumor-infiltrating lymphocytes were used to treat cancers. Genetically engineered T-cells were created expressing a T-cell receptor (TCR) recognizing a cancer cell-presented antigen or a chimeric T-cell receptor (CAR-T) harboring an antibody against cancer antigens.


In the last century, a global theory of the function of the immune system was progressively assembled, owing to the identification of the cells responsible for cellular and humoral immunity, the elucidation of mechanisms driving immune response to control infections and cancers, and the identification of checkpoint controls to protect normal cells from overactive immune responses.


In 1891, William B. Coley, an American surgeon and now known as the father of cancer immunotherapy, applied for the first time an immunotherapy approach to cure a cancer patient based on injections of Streptococcus pyogenes to boost the immune system.

QIMR Berghofer Medical Research Institute

A world-leading medical research institute, renowned for its major contributions in translational research on treatments of cancer, infectious diseases, and chronic diseases.

Medizinische Hochschule Hannover

One of the German leading universities focusing on biomedical engineering, regenerative medicine, infection, and immunological research.

Helmholtz Zentrum München-German Research Center for Environmental Health

Well-known for personalized therapies against major common diseases linked to environmental factors and genetic background.

The Agency for Science, Technology and Research, Singapore

Largest research body in Singapore, aiming to drive mission-oriented research that advances scientific discovery and technological innovation.

Stanford University School of Medicine

The School of Medicine improves health through leadership, diversity and collaborative discoveries and innovation in health care, education and research.


Take part in our mission to deliver more effective cancer care and
improve patient outcomes.